Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages 3736-3743

  Seto, Wai Kay ^a   Chan, Thomas S Y ^a   Hwang, Yu Yan ^a   Wong, Danny Ka Ho ^a   Fung, James ^a   Liu, Kevin Sze Hang ^a   Gill, Harinder ^a   Lam, Yuk Fai ^a   Lie, Albert K W ^a   Lai, Ching Lung ^a   Kwong, Yok Lam ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; MONOCLONAL ANTIBODY; VIRUS DNA;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHINESE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROSPECTIVE STUDY; RISK FACTOR; VIRUS REACTIVATION; AGED; BLOOD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 84911424291     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.7081     Document Type: Article

References (35)

1. Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105-112, 1975
2. Lau JY, Lai CL, Lin HJ, et al: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73:911-917, 1989
3. Yeo W, Chan PK, Ho WM, et al: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934, 2004
4. European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185, 2012
5. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
6. Raimondo G, Pollicino T, Cacciola I, et al: Occult hepatitis B virus infection. J Hepatol 46:160-170, 2007
7. Yuen MF, Wong DK, Fung J, et al: HBsAg seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterology 135:1192-1199, 2008
8. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined C.H.OP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
9. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with C.H.OP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
10. Edwards JC, Szczepanski L, Szechinski J, et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581, 2004
11. Taylor RP, Lindorfer M.A.: Drug insight: The mechanism of action of rituximab in autoimmune disease-The immune complex decoy hypothesis. Nat Clin Pract Rheumatol 3:86-95, 2007
12. Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001
13. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
14. Evens AM, Jovanovic BD, Su YC, et al: Rituximabassociated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170-1180, 2011
15. Kim SJ, Hsu C, Song YQ, et al: Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. Eur J Cancer 49:3486-3496, 2013
16. Hsu C, Tsou HH, Lin SJ, et al: Chemotherapyinduced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology 59:2092-2100, 2014
17. Seo DH, Whang DH, Song EY, et al: Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 51:1840-1846, 2011
18. Zhang H, Li Q, Sun J, et al: Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci 8:321-331, 2011
19. Luo Z, Xie Y, Deng M, et al: Prevalence of hepatitis B in the southeast of China: A populationbased study with a large sample size. Eur J Gastroenterol Hepatol 23:695-700, 2011
20. World Health Organization: Global alert and response: Hepatitis-Frequently asked questions. http://www.who.int/csr/disease/hepatitis/world-hepatitis-day/question-answer/en/
21. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
22. Tan D, Tan SY, Lim ST, et al: Management of B-cell non-Hodgkin lymphoma in Asia: Resourcestratified guidelines. Lancet Oncol 14:e548-e561, 2013
23. Ciotti M, Marcuccilli F, Guenci T, et al: Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B. J Clin Microbiol 46:1517-1519, 2008
24. Yeung P, Wong DK, Lai CL, et al: Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 203:646-654, 2011
25. Tai DI, Tsay PK, Chen WT, et al: Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. Am J Gastroenterol 105:1102-1109, 2010
26. Simonetti J, Bulkow L, McMahon BJ, et al: Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51:1531-1537, 2010
27. Müller AM, Ihorst G, Mertelsmann R, et al: Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution, and etiology. Ann Hematol 84:1-12, 2005
28. Shenoy PJ, Malik N, Nooka A, et al: Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117:2530-2540, 2011
29. Huang YH, Hsiao LT, Hong YC, et al: Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765-2772, 2013
30. Lai CL, Ratziu V, Yuen MF, et al: Viral hepatitis B. Lancet 362:2089-2094, 2003
31. Kabir A, Keshvari M, Kashani AH, et al: Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Hum Vaccin 4:379-383, 2008
32. Issa NC, Baden LR: Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Canc Netw 10:1447-1454, 2012
33. van Assen S, Holvast A, Benne CA, et al: Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75-81, 2010
34. Kusumoto S, Tanaka Y, Ueda R, et al: Reactivation of hepatitis B virus following rituximab-plussteroid combination chemotherapy. J Gastroenterol 46:9-16, 2011
35. European Consensus Group on Hepatitis B Immunity: Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 355:561-565, 2000